Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1953 1
1955 1
1957 1
1965 3
1966 4
1967 6
1968 16
1969 13
1970 14
1971 11
1972 14
1973 12
1974 26
1975 24
1976 16
1977 17
1978 23
1979 20
1980 17
1981 17
1982 33
1983 28
1984 39
1985 50
1986 49
1987 42
1988 56
1989 54
1990 73
1991 51
1992 72
1993 57
1994 70
1995 73
1996 83
1997 102
1998 71
1999 79
2000 86
2001 89
2002 81
2003 83
2004 99
2005 108
2006 123
2007 117
2008 116
2009 111
2010 156
2011 147
2012 148
2013 178
2014 194
2015 173
2016 196
2017 193
2018 216
2019 232
2020 219
2021 228
2022 251
2023 240
2024 76

Text availability

Article attribute

Article type

Publication date

Search Results

4,740 results

Results by year

Filters applied: . Clear all
Page 1
Diagnosis and Management of Cirrhosis and Its Complications: A Review.
Tapper EB, Parikh ND. Tapper EB, et al. JAMA. 2023 May 9;329(18):1589-1602. doi: 10.1001/jama.2023.5997. JAMA. 2023. PMID: 37159031 Review.
Approximately 1% to 4% of patients with cirrhosis develop hepatocellular carcinoma each year, which is associated with a 5-year survival of approximately 20%. In a 3-year randomized clinical trial of 201 patients with portal hypertension, nonsel …
Approximately 1% to 4% of patients with cirrhosis develop hepatocellular carcinoma each year, which is associated with a 5-year survival of …
The Use of Rifaximin in Patients With Cirrhosis.
Caraceni P, Vargas V, Solà E, Alessandria C, de Wit K, Trebicka J, Angeli P, Mookerjee RP, Durand F, Pose E, Krag A, Bajaj JS, Beuers U, Ginès P; Liverhope Consortium. Caraceni P, et al. Hepatology. 2021 Sep;74(3):1660-1673. doi: 10.1002/hep.31708. Epub 2021 Jun 7. Hepatology. 2021. PMID: 33421158 Free PMC article. Review.
Rifaximin is currently used worldwide in patients with cirrhosis for preventing recurrent HE because its efficacy and safety have been proven by large randomized clinical trials. In the last decade, experimental and clinical evidence suggest that rifaximin co …
Rifaximin is currently used worldwide in patients with cirrhosis for preventing recurrent HE because its efficacy and safety have been prove …
Hepatic fibrosis 2022: Unmet needs and a blueprint for the future.
Friedman SL, Pinzani M. Friedman SL, et al. Hepatology. 2022 Feb;75(2):473-488. doi: 10.1002/hep.32285. Epub 2022 Jan 11. Hepatology. 2022. PMID: 34923653 Review.
These include the need to better define cell-cell interactions and etiology-specific elements of fibrogenesis and their link to disease-specific drivers of portal hypertension. Success in treating viral hepatitis has revealed the remarkable capacity of the liver to …
These include the need to better define cell-cell interactions and etiology-specific elements of fibrogenesis and their link to disease-spec …
Therapeutic pipeline in nonalcoholic steatohepatitis.
Vuppalanchi R, Noureddin M, Alkhouri N, Sanyal AJ. Vuppalanchi R, et al. Nat Rev Gastroenterol Hepatol. 2021 Jun;18(6):373-392. doi: 10.1038/s41575-020-00408-y. Epub 2021 Feb 10. Nat Rev Gastroenterol Hepatol. 2021. PMID: 33568794 Review.
In addition, emerging therapies for NASH cirrhosis would have to demonstrate either reversal of fibrosis with associated reduction in portal hypertension or at least delay the progression with eventual decrease in liver-related outcomes. ...In this Review, we summar …
In addition, emerging therapies for NASH cirrhosis would have to demonstrate either reversal of fibrosis with associated reduction in por …
North American Practice-Based Recommendations for Transjugular Intrahepatic Portosystemic Shunts in Portal Hypertension.
Boike JR, Thornburg BG, Asrani SK, Fallon MB, Fortune BE, Izzy MJ, Verna EC, Abraldes JG, Allegretti AS, Bajaj JS, Biggins SW, Darcy MD, Farr MA, Farsad K, Garcia-Tsao G, Hall SA, Jadlowiec CC, Krowka MJ, Laberge J, Lee EW, Mulligan DC, Nadim MK, Northup PG, Salem R, Shatzel JJ, Shaw CJ, Simonetto DA, Susman J, Kolli KP, VanWagner LB; Advancing Liver Therapeutic Approaches (ALTA) Consortium. Boike JR, et al. Clin Gastroenterol Hepatol. 2022 Aug;20(8):1636-1662.e36. doi: 10.1016/j.cgh.2021.07.018. Epub 2021 Jul 15. Clin Gastroenterol Hepatol. 2022. PMID: 34274511 Free PMC article. Review.
Despite few high-quality randomized controlled trials to guide therapeutic decisions, transjugular intrahepatic portosystemic shunt (TIPS) creation has emerged as a crucial therapeutic option to treat complications of portal hypertension. ...Finally, future r …
Despite few high-quality randomized controlled trials to guide therapeutic decisions, transjugular intrahepatic portosystemic shunt ( …
Thrombocytopenia in chronic liver disease.
Peck-Radosavljevic M. Peck-Radosavljevic M. Liver Int. 2017 Jun;37(6):778-793. doi: 10.1111/liv.13317. Epub 2016 Dec 27. Liver Int. 2017. PMID: 27860293 Review.
The pathophysiology of thrombocytopenia in chronic liver disease has long been associated with the hypothesis of hypersplenism, where portal hypertension causes pooling and sequestration of all corpuscular elements of the blood, predominantly thrombocytes, in the en …
The pathophysiology of thrombocytopenia in chronic liver disease has long been associated with the hypothesis of hypersplenism, where por …
Carvedilol reduces the risk of decompensation and mortality in patients with compensated cirrhosis in a competing-risk meta-analysis.
Villanueva C, Torres F, Sarin SK, Shah HA, Tripathi D, Brujats A, Rodrigues SG, Bhardwaj A, Azam Z, Hayes PC, Jindal A, Abid S, Alvarado E, Bosch J; Carvedilol-IPD-MA-group and the Baveno Cooperation: an EASL Consortium. Villanueva C, et al. J Hepatol. 2022 Oct;77(4):1014-1025. doi: 10.1016/j.jhep.2022.05.021. Epub 2022 May 31. J Hepatol. 2022. PMID: 35661713 Free article.
Carvedilol might be particularly effective since its intrinsic vasodilatory activity may ameliorate hepatic vascular resistance, a major mechanism of portal hypertension in early cirrhosis. We assessed whether carvedilol may prevent decompensation and improve surviv …
Carvedilol might be particularly effective since its intrinsic vasodilatory activity may ameliorate hepatic vascular resistance, a major mec …
Emerging role of statin therapy in the prevention and management of cirrhosis, portal hypertension, and HCC.
Sharpton SR, Loomba R. Sharpton SR, et al. Hepatology. 2023 Dec 1;78(6):1896-1906. doi: 10.1097/HEP.0000000000000278. Epub 2023 Jan 3. Hepatology. 2023. PMID: 37013380 Review.
We review clinical evidence, derived primarily from retrospective cohort and population-based studies, on the association between statin use and reduction in risk for hepatic decompensation and mortality in persons with established cirrhosis. We also review evidence to dat …
We review clinical evidence, derived primarily from retrospective cohort and population-based studies, on the association between sta …
beta blockers to prevent decompensation of cirrhosis in patients with clinically significant portal hypertension (PREDESCI): a randomised, double-blind, placebo-controlled, multicentre trial.
Villanueva C, Albillos A, Genescà J, Garcia-Pagan JC, Calleja JL, Aracil C, Bañares R, Morillas RM, Poca M, Peñas B, Augustin S, Abraldes JG, Alvarado E, Torres F, Bosch J. Villanueva C, et al. Lancet. 2019 Apr 20;393(10181):1597-1608. doi: 10.1016/S0140-6736(18)31875-0. Epub 2019 Mar 22. Lancet. 2019. PMID: 30910320 Clinical Trial.
Clinically significant portal hypertension (CSPH), defined by a hepatic venous pressure gradient (HVPG) 10 mm Hg, is the strongest predictor of decompensation. ...METHODS: This study on beta blockers to prevent decompensation of cirrhosis with portal hyper …
Clinically significant portal hypertension (CSPH), defined by a hepatic venous pressure gradient (HVPG) 10 mm Hg, is the stron …
Corticosteroid therapy of alcoholic hepatitis.
Maddrey WC, Boitnott JK, Bedine MS, Weber FL Jr, Mezey E, White RI Jr. Maddrey WC, et al. Gastroenterology. 1978 Aug;75(2):193-9. Gastroenterology. 1978. PMID: 352788 Clinical Trial.
Fifty-five patients with alcoholic hepatitis were studied in a 28- to 32-day randomized double blind treatment trial comparing prednisolone (40 mg per day) with placebo therapy. ...These studies suggest that corticosteroid therapy does decrease early mortality in pa …
Fifty-five patients with alcoholic hepatitis were studied in a 28- to 32-day randomized double blind treatment trial comparing …
4,740 results